- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01841801
Evaluation of Experimental and Commercial Air-Activated, Adhesive Backed Heat Patches
March 15, 2017 updated by: Chattem, Inc.
To assess the safety and tolerability for the extended wear of an experimental air-activated self adhesive patch.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
157
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Pinellas Park, Florida, United States, 33781
- Radiant Research, Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants are 18 to 70 years of age;
- must be in general good health;
- must have absence of any visible disease that might be confused with a skin reaction to the test material;
- back region must be free from excessive hair, cuts, tatoos, or other aberrations;
- must understand and sign Informed Consent;
- must be considered dependable and able to follow directions;
- Participants assigned to the thermocouples must be willing to restrict their activity for the 8 hour patch wear time so that the thermocouples do not come loose;
- Participants assigned to the thermocouples must be willing to wear a pouch containing the thermostat and thermocouple wiring for the entire 8 hour period and to return all study supplies to the site at visit 15. If the items are not returned subject may be invoiced for the value of the unit;
- must be willing to not wear any topical products such as lotions, sunscreens, etc. in the test area while participating in the study;
- must agree to use an adequate means of birth control which include: abstinence, partner vasectomy, Intrauterine Device, hormonal implant devices/injections, regular use of birth control pills, birth control patches or condoms with a spermicidal agent;
- Participants are willing to come in each day with a CLEAN back;
- Participants who are 55 years of age and older, agree to supply a t-shirt to wear at visit two that can be marked on with a marker, and to use that t-shirt or supply others at the morning visits (visits 4, 6, 8, 10, 12, 14).
Exclusion Criteria:
- Participants with known skin sensitivity to adhesion products;
- Participants with any skin abnormality likely to be aggravated by the study material such as dermatological disease or infection, rash, atrophic, fragile, or abnormally dry skin, cuts or abrasions at the treatment site;
- Participants who are pregnant or nursing, oral interview only;
- Participants with diabetes or poor circulation;
- Participants unable to tolerate conditions of protocol;
- Participants viewed by the investigator as not being suitable for the study;
- Participants who have had active skin cancer including basal cell carcinoma, or other cancer within one year;
- Participants who are currently participating in another clinical trial;
- Participants who routinely use anti-inflammatory medications (within 5 days of study start (81mg aspirin is okay)) or immunosuppressive or antihistamine medications within 3 weeks prior to study start (steroid nose/eye drops are ok);
- Participants who currently use allergy injections;
- Participants with history of severe asthma;
- Participants with active or uncontrolled immunologic disorders i.e. AIDS, HIV positive, systemic lupus erythematosus, rheumatoid arthritis;
- Participants with uncontrolled thyroid disease;
- Participants who have any clinically significant chronic illness which could place the subject at increased risk during participation or result in inappropriate dermal response during the study;
- Participants who have used topical medications at the test sites within the past 14 days;
- Participants who have lower midline abdominal pinnicula which may interfere with heat patch/wrap application and or evaluation;
- Participants who have a pacemaker, defibrillator or other implantable medical device;
- Participants who have allergies to latex, polyethylene, polypropylene, nickel, chromium or aluminum.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Marketed Thermal Adhesive Patch
Group of subjects wearing comparative predicate device for 8 hours daily for 7 days.
|
Other Names:
|
|
Experimental: Thermal Adhesive Patch
Group of subjects wearing the experimental patch for 8 hours daily for 7 days.
|
|
|
Placebo Comparator: Placebo Patch
Group of subjects wearing the placebo patch for 8 hours daily for 7 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Irritation Evaluation
Time Frame: 7 days - 8 hours each day
|
A trained skin grader will apply a predetermined scale to the observed skin reactions in the test areas under light supplied by a 100-watt incandescent blue bulb.
|
7 days - 8 hours each day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adhesion Evaluation
Time Frame: after 8 hours
|
Adhesion will be evaluated to a predetermined scale when the subjects return for visits; after approximately 8 hours of wear time.
|
after 8 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heat Intensity
Time Frame: 8 hours
|
Assessed using thermocouple sensors worn between the patch and subject's skin with readings taken every 15 minutes.
|
8 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Daniel J Hogan, MD, Radiant Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2012
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
April 23, 2013
First Submitted That Met QC Criteria
April 24, 2013
First Posted (Estimate)
April 29, 2013
Study Record Updates
Last Update Posted (Actual)
March 17, 2017
Last Update Submitted That Met QC Criteria
March 15, 2017
Last Verified
April 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- 2012007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tolerability
-
AstraZenecaCompletedTolerabilityUnited States
-
National Center for Occupational Health and Infection...VA Office of Research and DevelopmentCompletedTolerability | ComfortUnited States
-
Tiziana Life Sciences LTDCompletedTolerability | SafetyUnited States
-
AnaMar ABCovanceCompletedTolerability | SafetyUnited Kingdom
-
Repros Therapeutics Inc.CompletedPharmacokinetics | TolerabilityUnited States
-
Sichuan Huiyu Pharmaceutical Co., LtdRecruitingEfficacy | Tolerability | SafetyChina
-
JemincareRecruitingSafety and TolerabilityChina
-
Island PharmaceuticalsBeyond Drug DevelopmentCompletedSafety and TolerabilityAustralia
-
MDI Therapeutics, Inc.CompletedSafety and TolerabilityUnited States
-
Usona InstituteCompletedPharmacokinetics | Tolerability | SafetyUnited States
Clinical Trials on Placebo Patch
-
En Chu Kong HospitalCompleted
-
University of ZurichCompletedAllergic RhinoconjunctivitisSwitzerland
-
Fayoum UniversityNot yet recruitingImpacted Third Molar Tooth
-
Frontier Biotechnologies Inc.CompletedChronic Low Back PainUnited States
-
Sheba Medical CenterTerminated
-
Natural Immune Systems IncNot yet recruiting
-
Natural Immune Systems IncRecruitingAntioxidant StatusUnited States
-
Chattem, Inc.CompletedTolerability | Adhesiveness | Dermal Irritation | Effects of HeatUnited States
-
SamA Pharmaceutical Co., LtdRecruitingAcute BronchitisSouth Korea
-
Chinese PLA General HospitalRecruitingPostoperative DeliriumChina